Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Running, not enrolling · Phase 2
Conditions studied: Cushing Syndrome
In brief
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Key facts
- Study ID
- NCT03604198
- Run by
- Corcept Therapeutics
- People needed
- 125
- Starts
- 2018-05-07
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-04-21
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Major Inclusion Criteria:
- Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome with at least 80% compliance with the dosing schedule.
- According to the Investigator's opinion will benefit from continuing treatment with relacorilant
You may not qualify if…
- Major Exclusion Criteria:
- Premature discontinuation from a relacorilant parent study.
- Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
- Has poorly controlled hypertension
- Has Stage ≥ 4 renal failure
Where it is running
- Site 49 — Phoenix, Arizona, United States
- Site 35 — Stanford, California, United States
- Site 39 — Torrance, California, United States
- Site 50 — Miami, Florida, United States
- Site 10 — Atlanta, Georgia, United States
- Site 9 — Chicago, Illinois, United States
- Site 1 — Indianapolis, Indiana, United States
- Site 5 — Metairie, Louisiana, United States
- Site 27 — Baltimore, Maryland, United States
- Site 13 — Fall River, Massachusetts, United States
- Site 8 — Ann Arbor, Michigan, United States
- Site 36 — Rochester, Minnesota, United States
- Site 34 — Jackson, Mississippi, United States
- Site 3 — St Louis, Missouri, United States
- Site 55 — Reno, Nevada, United States
- Site 6 — Albany, New York, United States
- Site 24 — New York, New York, United States
- Site 4 — Wilmington, North Carolina, United States
- Site 43 — Cleveland, Ohio, United States
- Site 2 — Pittsburgh, Pennsylvania, United States
- Site 46 — Pittsburgh, Pennsylvania, United States
- Site 11 — Dallas, Texas, United States
- Site 7 — El Paso, Texas, United States
- Site 32 — Fort Worth, Texas, United States
- Site 12 — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.